16 results
6-K
EX-99.1
MOR
Morphosys AG
21 Nov 23
Topline Results Phase 3 MANIFEST-2 Study Pelabresib in First-Line Myelofibrosis November 2023 Gail, Living with Myelofibrosis since 2018
10:08am
OPEN-LABEL, SINGLE-ARM PHASE I/II STUDY (N = 107) HR, hazard ratio; OS, overall survival. | Verstovsek S, et al. Blood. 2012;120:1202-1209.
11
6-K/A
EX-99.1
MOR
Morphosys AG
7 May 21
First Quarter Interim Statement
11:58am
been reached in the tafasitamab-lenalidomide combination as compared to 9.3 months in the lenalidomide monotherapy (hazard ratio 0.47).
MorphoSys – I
6-K
EX-99.1
MOR
Morphosys AG
5 May 21
First Quarter Interim Statement
4:21pm
been reached in the tafasitamab-lenalidomide combination as compared to 9.3 months in the lenalidomide monotherapy (hazard ratio 0.47).
MorphoSys – I
6-K
EX-99.1
MOR
Morphosys AG
23 Mar 21
Current report (foreign)
3:53pm
as compared to 9.3 months in the lenalidomide monotherapy (hazard ratio 0.47). MorphoSys AG – Planegg — Annual Financial Statements as of December 31
6-K
EX-99.1
rxkb9f9y m00d
22 Mar 21
Current report (foreign)
12:42pm
6-K
EX-99.1
zn50rs5ezf 45pr
12 Nov 20
Third Quarter Interim Statement
11:30am
6-K
EX-99.1
qnypvhh 3fqr
5 Aug 20
Half-Year Report January – June 2020
4:18pm
6-K
EX-99.1
tjxevueme mj7yx4
6 May 20
First Quarter Interim Statement
4:19pm
6-K
EX-99.1
6dxzgh hga65usxp00y
27 Mar 20
Current report (foreign)
3:29pm
6-K
EX-99.1
l5wdh 2ona5oic
20 Mar 20
Current report (foreign)
2:15pm
6-K
EX-99.1
n84q 25xao6
30 Oct 19
Third Quarter Interim Statement
10:03am
6-K
EX-99.1
3ussi
30 Oct 19
Current report (foreign)
6:13am
6-K
EX-99.2
q72ln1m
30 Oct 19
Current report (foreign)
6:13am
- Prev
- 1
- Next